2024-517047-30-01招募中1 期
PSEUDOVAX – A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI
Oslo University Hospital HF1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Incidence (rate) of IMP-related adverse events
研究概览
简要总结
To assess safety and tolerability of sequential treatment with Pseudovax/GM-CSF and tislelizumab in order to measure immune activation following study treatment.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •The subject is ≥ 18 years of age on the day of signing the informed consent form, able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.
- •8b). b. Male subject: Sexually active males must be willing to use a condom during sex for the duration of the study and for ≥ 6 months after the last dose of IMP. Males must also be willing to abstain from donating sperm during the same period.
- •Confirmed diagnosis of recurrent or non-resectable PMP with no other available treatment options that are expected to be efficacious.
- •The subject’s tumor must carry a mutation in the GNAS oncogene*
- •Subjects must have peritoneal tumor distribution at screening that, in the opinion of the Investigator, is suitable for repeat biopsies: Up to 3 biopsies of target tissue are planned for subjects that complete the study.
- •Adequate organ, bone marrow, liver, and renal function at screening, including: a). Absolute neutrophil count: ≥ 1,5 x10^9/L. b). Platelets: ≥ 100 x10^9/L. c). Hemoglobin: ≥ 9 x10^9/L. d). Creatinine ≤ 1,5 upper limit normal (ULN) OR measured/calculated GFR ≥60 mL/min. e). Albumin ≥ 30 g/L. f). Total bilirubin ≤ 1,5 ULN. g). ASAT and ALAT ≤ 3 ULN. h). International Normalized Ratio (INR) ≤ 1,5 ULN and Activated Partial Thromboplastin Time (TT) ≤ 1,5 ULN unless subject is receiving anticoagulant therapy.
- •ECOG performance status of 0 or
- •Life expectancy of >6 months, at the time of signing the informed consent.
- •Women of childbearing potential must have a negative serum pregnancy test within 48 hours of the first study intervention, and must not be breast-feeding.
- •8a). a. Female participant: i. Unless documented not to have childbearing potential: Subject is willing to use contraceptive measures for the duration of the study, and ≥ 6 months after the last dose of IMP, as prescribed by the protocol (according to the applicable guidance: CTFG, 2020). The Investigator should counsel women of childbearing potential of the importance of pregnancy prevention. ii. Women of childbearing potential must have a negative serum pregnancy test within 48 hours of the first study intervention.
排除标准
- •Patient has Eastern Cooperative Oncology Group performance status 2 or worse.
- •Known active hepatitis B or C, or is known to be HIV-positive.
- •Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of IMP. Note: Subjects who are currently or have previously been on any of the following steroid regimens are not excluded: Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent); Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption; Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen).
- •Active autoimmune diseases or history of autoimmune diseases that may relapse. Note: Subjects with the following diseases are not excluded and may proceed to further screening, controlled Type I diabetes, hypothyroidism (provided it is managed with hormone replacement therapy only), controlled celiac disease skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia), any other disease that is not expected to recur in the absence of external triggering factors.
- •Severe infections within 4 weeks before first dose of IMP, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
- •Therapeutic oral or intravenous antibiotics within 2 weeks before first dose of IMP
- •Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of IMP.
- •Prior allogeneic stem cell transplantation or organ transplantation
- •Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤ 28 days before first dose of IMP.
- •Pulmonary embolism ≤ 28 days before first dose of IMP.
- •History of acute myocardial infarction ≤ 6 months before first dose of IMP.
- •Diagnosis of immunodeficiency.
- •History of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 6) ≤ 6 months before first dose of IMP.
- •Subject has had any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before first dose of IMP.
- •Severe hypersensitivity (≥grade 3) to chemotherapy, any other biologic drug or the contents or preservatives of any of the study drugs.
- •History of cerebrovascular accident ≤ 6 months before first dose of IMP.
- •Subject has underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that, will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs or result in insufficient or might impair compliance with study conduct.
- •Any reason why, in the opinion of the investigator, the patient should not participate.
- •History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.
- •Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.
- •Blood transfusion or growth factor support ≤ 14 days before sample collection at screening.
- •Active malignancy the past 3 years except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)
- •Enrollment in another interventional trial that, in the opinion of the Investigator, could influence the outcome of this study.
- •Subject has within the last 30 days received any other interventional therapy that, in the opinion of the Investigator, could influence the outcome of this study.
- •Pregnancy or lactating female.
结局指标
主要结局
Incidence (rate) of IMP-related adverse events
Incidence (rate) of IMP-related adverse events
T cell responses against the vaccine peptide in blood samples and skin
T cell responses against the vaccine peptide in blood samples and skin
次要结局
- Progression-free survival, measured as the number of months from date of first treatment until disease progression or death from any cause
研究者
Geir Olav Hjortland
Scientific
Oslo University Hospital HF
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE)non-small cell lung cancer2024-517561-16-00AIO-Studien gGmbH50
招募中
2 期
Pan tumor Roll Over Study2023-506914-32-00Bristol Myers Squibb International Corporation306
招募中
1 期
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07288359Novartis Pharmaceuticals205
招募中
2 期
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerNCT07267078Peking Union Medical College Hospital45
招募中
1 期
FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patients and other tumor entities carrying the oncogenic driver fusion2024-519387-41-00Universitaetsklinikum Tuebingen AöR20